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ABSTRACT: This study was undertaken to investigate
the prevalence of sequence variants in LCA5 in patients
with Leber congenital amaurosis (LCA), early-onset reti-
nal dystrophy (EORD), and autosomal recessive retinitis
pigmentosa (arRP); to delineate the ocular phenotypes;
and to provide an overview of all published LCA5 vari-
ants in an online database. Patients underwent standard
ophthalmic evaluations after providing informed consent.
In selected patients, optical coherence tomography (OCT)
and fundus autofluorescence imaging were possible. DNA
samples from 797 unrelated patients with LCA and 211
with the various types of retinitis pigmentosa (RP) were
screened by Sanger sequence analysis of all LCA5 exons
and intron/exon junctions. Some LCA patients were pre-
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screened by APEX technology or selected based on ho-
mozygosity mapping. In silico analyses were performed to
assess the pathogenicity of the variants. Segregation anal-
ysis was performed where possible. Published and novel
LCA5 variants were collected, amended for their cor-
rect nomenclature, and listed in a Leiden Open Variation
Database (LOVD). Sequence analysis identified 18 new
probands with 19 different LCA5 variants. Seventeen of
the 19 LCA5 variants were novel. Except for two mis-
sense variants and one splice site variant, all variants were
protein-truncating mutations. Most patients expressed a
severe phenotype, typical of LCA. However, some LCA
subjects had better vision and intact inner segment/outer
segment (IS/OS) junctions on OCT imaging. In two fami-
lies with LCA5 variants, the phenotype was more compat-
ible with EORD with affected individuals displaying pre-
served islands of retinal pigment epithelium. One of the
families with a milder phenotype harbored a homozygous
splice site mutation; a second family was found to have a
combination of a stop mutation and a missense mutation.
This is the largest LCA5 study to date. We sequenced
1,008 patients (797 with LCA, 211 with arRP) and iden-
tified 18 probands with LCA5 mutations. Mutations in
LCA5 are a rare cause of childhood retinal dystrophy ac-
counting for∼2% of disease in this cohort, and the major-
ity of LCA5 mutations are likely null. The LCA5 protein
truncating mutations are predominantly associated with
LCA. However, in two families with the milder EORD,
the LCA5 gene analysis revealed a homozygous splice site
mutation in one and a stop mutation in combination with a
missense mutation in a second family, suggesting that this
C© 2013 WILEY PERIODICALS, INC.
milder phenotype is due to residual function of lebercilin
and expanding the currently known phenotypic spectrum
to include the milder early onset RP. Some patients have
remaining foveal cone structures (intact IS/OS junctions
on OCT imaging) and remaining visual acuities, which
may bode well for upcoming treatment trials.
HumMutat 34:1537–1546, 2013. C© 2013Wiley Periodicals, Inc.
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Introduction
Leber congenital amaurosis (LCA) is an infantile onset, severe
retinal dystrophy that presents with profound visual impairment,
inability to fixate and nystagmus from birth or within the first few
weeks of life [von Leber, 1869]. It is the most severe form of a
spectrum of disorders arising within the first few years of life, which
affect both rod and cone photoreceptors, termed childhood or early-
onset retinal dystrophy (EORD) [Gu et al., 1997]. The term juvenile
retinitis pigmentosa (RP) has also been used to describe EORD.
Autosomal recessive RP (arRP) falls into this spectrum of disorders
with onset typically later in childhood or beyond. LCA accounts
for 3%–5% of childhood blindness in the developed world and has
an incidence of two to three per 100,000 live births [Heckenlively
et al., 1988]. Depending on the age at diagnosis, the retinal ap-
pearance may be normal or there may be a variety of abnormalities
including vascular narrowing, macular atrophy, peripheral white
dots at the level of the retinal pigment epithelium (RPE), and reti-
nal pigmentation. The full-field electroretinogram (ERG) is usually
nondetectable (<10 μV) with conventional ERG testing or severely
decreased before the age of 1 year [Foxman et al., 1985; Franceschetti
and Dieterle, 1954].
LCA is predominantly inherited as an autosomal recessive trait,
although rare dominant forms have been reported [Swaroop et al.,
1999]. Nineteen causative genes have thus far been reported: AIPL1
[MIM #604392] [Sohocki et al., 2000], CABP4 [MIM #608965]
[Aldahmesh et al., 2010], CEP290 [MIM #610142] [den Hollan-
der et al., 2006], CRB1 [MIM #604210] [den Hollander et al.,
2001], CRX [MIM #602225] [Freund et al., 1998], GUCY2D [MIM
#600179] [Perrault et al., 1996], IMPDH1 [MIM #146690] [Bowne
et al., 2006], IQCB1 [MIM #609237] [Estrada-Cuzcano et al., 2011],
KCNJ13 [MIM #603208] [Sergouniotis et al., 2011], LCA5 [MIM
#611408] [den Hollander et al., 2007], LRAT [MIM #604863]
[Thompson et al., 2001],MERTK [MIM #604705] [Gal et al., 2000],
NMNAT1 [MIM #608700] [Chiang et al., 2012; Falk et al., 2012;
Koenekoop et al., 2012; Perrault et al., 2012], RD3 [MIM #180040]
[Friedman et al., 2006], RDH12 [MIM #608830] [Janecke et al.,
2004], RPGRIP1 [MIM #605446] [Dryja et al., 2001], RPE65 [MIM
#180069] [Gu et al., 1997; Marlhens et al., 1997], SPATA7 [MIM
#609868] [Wang et al., 2009], and TULP1 [MIM #602280] [Hanein
et al., 2004]. Interestingly, mutations in some of these genes, such
as CEP290 [Littink et al., 2010], CRB1 [den Hollander et al., 1999],
LRAT [Thompson et al., 2001], MERTK [Gal et al., 2000], RPE65
[Morimura et al., 1998], and SPATA7 [Wang et al., 2009], may also
be associated with milder forms of retinal dystrophy.
The LCA5 locus (MIM #604537) was mapped to chromosome
6q11-q16 by traditional linkage studies in a multigenerational kin-
dred of the Old Order River Brethren [Dharmaraj et al., 2000].
Further homozygosity mapping in consanguineous and noncon-
sanguineous families led to a refinement of the critical region [den
Hollander et al., 2007; Mohamed et al., 2003] and the causative
gene, LCA5, was identified [den Hollander et al., 2007]. LCA5 com-
prises nine exons, seven of which encode Lebercilin, a 697 amino
acid protein that contains four coiled-coil domains [den Hollan-
der et al., 2007]. Lebercilin is widely expressed in human tissues
including cilia. In situ hybridization of mouse embryos at day
12.5 postcoitum detected almost ubiquitous, low-level staining. At
embryonic day 14.5, staining of the eye, inner ear, kidney, and re-
gions of the central and peripheral neural system, gut and the cil-
iated epithelium of the nasopharynx, trachea, and lungs was more
pronounced. In the adult eye, expression was limited to the pho-
toreceptor cell layer. In ciliated cell lines, lebercilin localizes to the
ciliary axoneme. In mouse and rat retina, it is found between the
outer and inner segments of the photoreceptor layer. In a human
embryonic kidney cell line, HEK293, recombinant lebercilin was
found to interact with 24 proteins, many of which are associated
with centrosomal or ciliary functions, and the intraflagellar trans-
port machinery [Boldt et al., 2011]. Lca5 inactivation in mice led to
very severe and rapid retinal degeneration. At 1 month postnatally,
there was a significant reduction in photoreceptor cells, and after 4
months, the photoreceptor layer was completely absent [Boldt et al.,
2011].
To date, 12 different mutations in LCA5 have been reported. In
patients of all families except one, the phenotype has been typical
of LCA [Abu-Safieh et al., 2013; Ahmad et al., 2011; den Hollander
et al., 2007; Gerber et al., 2007; Jacobson et al., 2009; Li et al.,
2011; Ramprasad et al., 2008; Vallespin et al., 2010a; Vallespin et al.,
2010b]. Despite its ubiquitous expression and its crucial functions
in the cilia [Boldt et al., 2011], the phenotype associated with LCA5
mutations has thus far been confined to the retina. In this paper,
we present the results of screening for mutations in LCA5 in a
large number of subjects with LCA and EORD (n = 797), and arRP
(n = 211), and describe the associated phenotypes.
Materials and Methods
Patients
In total, we sequenced 1,008 patients. We ascertained 797
probands with LCA and EORD, living in Belgium (n = 47), Canada
and the USA (n = 300), Germany (n = 65), The Netherlands (n = 54),
South Africa (n = 18), Sweden (n = 20), Switzerland (n = 42), China
(n = 100), Pakistan (n = 1), and the United Kingdom (n = 150).
In addition, we included 211 persons with isolated or arRP from
The Netherlands. Many LCA and arRP patients were not originally
from their current place of residence and were actually from India,
Pakistan, Russia, and other countries. Approximately 50% of the
persons with LCA were previously analyzed using various Asper
Ophthalmics LCA allele-specific primer extension (APEX) muta-
tion chips. None of the DNAs of persons with arRP were previously
analyzed for LCA5 mutations using APEX. LCA, EORD, and RP
may be considered a continuum of retinal dystrophies, in which
LCA represents the extreme end of severity, as far as the age of onset
and functional outcome are concerned. In our current study, LCA
was diagnosed in children who were born with severe visual loss,
inability to fixate at around 6weeks of age, nystagmus, and absent or
nondetectable ERGs. EORDwas diagnosed in children bornwith re-
duced, but clinically identifiable, visual function and fixation, with
or without nystagmus, and with progressive night blindness and
subsequent vision loss. arRP was diagnosed in patients without nys-
tagmus, a variable onset of progressive night blindness and visual
loss after the age of 2 years.
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Clinical Investigations
All patients and family members provided informed consent as
part of research projects approved by the local research ethics com-
mittees, and the study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki. Clinical evaluation, includ-
ing monocular best-corrected visual acuity by projected Snellen
charts, slit-lamp biomicroscopy, and fundus examination was per-
formed on all patients who could cooperate with testing. Where
possible, patients underwent retinal imaging using a Topcon TRC
501A retinal camera (Topcon Corporation, Tokyo, Japan), optical
coherence tomography using a SPECTRALIS R© Spectral domain op-
tical coherence tomography (OCT) scanner (Heidelberg Engineer-
ing, Heidelberg, Germany), and retinal autofluorescence imaging
using a confocal scanning laser ophthalmoscope (Zeiss Prototype;
Carl Zeiss Inc., Oberkochen, Germany). Pattern and full-field elec-
troretinogram (PERG and ERG) were performed, where possible,
using the recommendations of the International Society for Clinical
Electrophysiology of Vision (ISCEV) or a modified Paediatric ERG
protocol with skin electrodes as previously described [Flitcroft et al.,
2005; Kriss, 1994; Marmor et al., 2009]. Patient #14 (Berman-Gund
Laboratory ID: 048–038) was evaluated by full-field ERG testing
using Burian Allen contact lens electrodes, narrow band-passed
filtering, and computer averaging that can extend the range of de-
tectability of 30 Hz cone ERGs to 0.05 μV [Berson et al., 1993].
Goldmann perimetry was performed in patient #16.
Blood samples were collected in EDTA tubes and DNA was ex-
tracted using the Puregene blood extraction kit (Invitrogen, Paisley,
UK) following manufacturer’s instructions, or by a standard salting
out procedure [Miller et al., 1988].
Mutation Screening
Nucleotide numbering reflects cDNA with +1 corresponding
to the A of the ATG translation initiation codon (RefSeq NM
181714.3), according to journal guidelines (www.hgvs.org/
mutnomen). The initiation codon is codon 1. Primers used to am-
plify the coding exons and the intron–exon boundaries of LCA5
were designed using those published previously [den Hollander
et al., 2007]. In addition, 194 persons with LCA and 94 persons
with arRP were analyzed for the presence of an exon 1 deletion
identified in the original LCA5 family [den Hollander et al., 2007].
To this end, primers 5′-TTCCGTGCAATTTAGGGATT-3′ and 5′-
CGGGGTTTTTGTTTTGTTTG-3′ were designed to amplify a dele-
tion breakpoint fragment of 117 bp. All standard polymerase chain
reactions (PCR) were performed in a total volume of 30μl contain-
ing 200 μM dNTPs (Bioline, London, UK), 20 μM of each primer,
1× reaction buffer with 1.5 mM MgCl2 (Bioline) with 1 unit of
Biotaq (Bioline) and 100 ng of DNA. PCR was carried out on a
PTC200 DNA engine thermal cycler (Bio-Rad, Hemel Hempstead,
UK). Cycling conditionswere as follows: 5min denaturation at 94◦C
followed by 35 cycles of 94◦C for 30 sec, annealing temperature for
30 sec, and extension at 72◦C for 30 sec. A final extension of 72◦C
for 5 min completed the cycling conditions.
PCR products were visualized on a 2% agarose gel containing
0.05% ethidium bromide. The products were cleaned using multi-
screen PCR filter plates (Millipore, Watford, UK) prior to sequenc-
ing. PCR products were sequenced directly using the ABI Prism Big
Dye terminator Kit (V3.1, Applied Biosystems, Foster City, CA) in
a 10-μl reaction. Samples were purified using the Montage cleanup
kit (Millipore) prior to being run on anABI applied biosystems 3730
DNA sequencer (Applied Biosystems). Electropherograms were an-
alyzed for sequence changes usingDNAStar computational software
(DNAStar, Inc., Madison, WI). Any sequence changes identified
were checked visually.
Mutations were tested in normal controls when possible, and
cosegregation was performed in the families, when possible. Muta-
tion frequencies were analyzed in the exome variant server database,
1000 genomes database, and dbSNP database. In silico analyses
were then performed to assess pathogenicity, including Blosum62,
Polyphen2, and PhyloP.
Patient #1 was originally identified to harbor a heterozygous mu-
tation in LCA5 by microarray analysis using the Asper LCA Apex
chip. His second mutation was identified following LCA5 sequence
analysis. Patient #18 was selected for LCA5 sequence analysis be-
cause homozygosity mapping of two affected persons (IV:2 and
IV:3) of family W12-2240 (Fig. 1) showed a large, significant ho-
mozygous region surrounding LCA5. To identify this region, we had
Figure 1. Pedigrees of patients #7 and #18. A: An EORD family with proband #7 is indicated with an arrow. A half-brother and cousin also show
the clinical characteristics of arRP and carry the splice variant (M: c.1231+2insT) in the homozygous state. One unaffected brother and the father
of the proband carry this variant in the heterozygous state. B: An LCA family with proband #18. A frequent Pakistani LCA5 variant (c.1151del) is
found in the homozygous state in three persons with LCA and in the heterozygous state in five unaffected persons.
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Table 1. Mutations Identified in LCA5
Allele 1 Allele 2
Patient DNA variant Protein variant DNA variant Protein variant Segregation Reference (allele 1/allele 2)
1 c.835C>T p.(Gln279∗) c.1756A>T p.(Lys586∗) Yes den Hollander et al., 2007/novel
2 c.1151delC p.(Pro384Glnfs∗18) c.1151delC p.(Pro384Glnfs∗18) Yes den Hollander et al., 2007
3 c.633 639del p.(Glu211Aspfs∗13) c.633 639del p.(Glu211Aspfs∗13) M-yes; F-NT Novel
4 c.3G>A p.(Met1Ile) c.835C>T p.(Gln279∗) NT Novel/den Hollander et al., 2007
5 c.1676C>A p.(Ser559∗) c.1676C>A p.(Ser559∗) Yes Novel
6 c.367C>T p.(Gln123∗) c.1756T>A p.(Lys586∗) NT Novel/novel
7 c.1231+2insT p.? c.1231+2insT p.? Yes Novel
8 c.142A>T p.(Arg48∗) c.142A>T p.(Arg48∗) NT Novel
9 c.142A>T p.(Arg48∗) c.142A>T p.(Arg48∗) NT Novel
10 c.1543 1544delinsA p.(Ser515Lysfs∗78) c.1543 1544delinsA p.(Ser515Lysfs∗78) NT Novel
11 c.795T>G p.(Tyr265∗) c.1759 1760insAG p.(Leu587Glnfs∗7) NT Novel/novel
12 c.835C>T p.(Gln279∗) c.835C>T p.(Gln279∗) NT den Hollander et al., 2007
13 c.42 45del p.(Lys15Glnfs∗95) c.1207C>T p.(Gln403∗) NT Novel/novel
14 c.1730dup p.(Leu577Phefs∗12) + + NT Novel
15 c.2011C>T p.(Arg671∗) + + NT Novel
16 c.69C>G p.(Tyr23∗) c.491A>G p.(His164Arg) NT Novel/novel
17 c.439 449dup p.(Glu151∗) c.439 449dup p.(Glu151∗) Yes Novel
18 c.1151delC p.(Pro384Glnfs∗18) c.1151delC p.(Pro384Glnfs∗18) Yes den Hollander et al., 2007
Mutation nomenclature is based on NM_181714.3.
F, father; M, mother; NT, not tested; +, not identified.
employed the CytoScan R© High-Density array containing probes to
detect 750,000 single-nucleotide polymorphisms (Affymetrix, Santa
Clara, CA).
Results
Mutational Analysis
A total of 797 patients with LCA and EORD and 211 with arRP
were screened for sequence variants in protein-coding exons (i.e.,
exons 3 through 9) of LCA5. Sixteen probands were identified with
two disease-causing variants. In all, 19 different LCA5 variants were
identified (Table 1); 17 of these variants are novel. Homozygous
variants were found in 10 probands, compound heterozygous vari-
ants in six probands, and heterozygous protein truncating variants
in two probands (Table 1).
All but two mutations were predicted to lead to premature ter-
mination of the lebercilin protein. One of the missense mutations
that we identified was in patient #4 involving the first amino acid
of the lebercilin protein (p.Met1Ile). The other missense change is a
novel change in patient #16 involving a histidine to arginine change
at position 164 (p.His164Arg). The underlying c.491A>G variant
was not found in 8,600 alleles of “control” individuals in the Exome
Variant Server database and once in the 1000 genomes database
(rs183669161). Unfortunately, we do not have parental DNA to test
for segregation. The PhyloP score of c.491A is 3.92, Polyphen2 pre-
dicts damage, and the histidine at position 164 is fully conserved
between human, rhesus, mouse, dog, opossum, chicken, Western
clawed frog, and zebrafish. In an affected half-brother (IV:1) and an
affected cousin (V:1) of patient #7 (Fig. 1A), the same homozygous
splice site variant (c.1231+2insT) was found, and two unaffected
persons carried this variant in the heterozygous state. This vari-
ant is predicted to completely inactivate this splice site based on
SpliceSiteFinder, MaxEntSplice, and NNSplice analysis. Homozy-
gositymapping using DNA from two persons with LCA from family
W12-2240 (Fig. 1B: patients IV:2 and IV:3) yielded 10 shared ho-
mozygous regions larger than 5 Mb. The third largest homozygous
region on chromosome 6 (18.9Mb) encompassed LCA5. In all three
affected individuals (Fig. 1B), the c.1151delC (p.Pro384Glnfs∗18)
variant was identified in the homozygous state in LCA5. This vari-
ant was present in the heterozygous state in five unaffectedmembers
(Fig. 1B).
The ethnic origins of the 18 probands with LCA5mutations were
as follows: European Caucasian: 7 (British, Slovakian-Romani, and
Spanish); Asian: 7 (Pakistan, Afghanistan, Indian-Mauritian, Iraqi,
Taiwanese, and Chinese); North American: 3; Mexican: 1.
Clinical Phenotype
Of the 18 probands with LCA5 variants identified in this study,
all but two patients had a clinical diagnosis of LCA, with onset of
severe visual loss at birth or within the first few months of life,
and nystagmus (Table 2). However, patients #7 and #16 received a
diagnosis of EORD. Patient #7 was born with congenital nystagmus,
and developed night blindness at the age of 3, visual field loss at
the age of 6, and visual loss at the age of 8. In patient #16, the
visual loss started after the age of 40 years. In addition, patient #16
did not have nystagmus. All of our LCA and EORD patients had
nyctalopia and severe visual field constriction. General health was
good in themajority of patients, except in patient #2 who had global
developmental delay and patient #3 who had behavioral problems.
Fourteen of the 16 LCA patients were legally blind with visual acuity
ranging from 1.0 logMAR to light perception. One patient, #11,
with LCA and nystagmus, had visual acuities of 0.48 right (20/60)
and 0.54 left (20/70) at the age of 6 years (Table 2). Patient #16, with
EORD, had a visual acuity of 0.30 (20/40) at the age of 55 years.Most
patients had a hypermetropic refraction (Table 2). The high myopic
correction in patient #6 may be attributed to keratoconus. A full-
field ERG was performed in eight patients and was nondetectable
(<10 μV) with conventional ERG testing in five patients. A small
cone ERG response could be quantified in patient #14 and trace
cone ERG responses (unquantified) could be detected in patient
#16 (Table 2). Anterior segments were normal in all but one of the
oldest patients (patient #6), who had bilateral keratoconus at the age
of 37 years. This patient also developed bilateral nuclear sclerotic
and posterior subcapsular lenticular opacities in adulthood.
Fundus examination most commonly revealed widespread reti-
nal pigment epithelial atrophy and granularity, with peculiar, small,
white dots at the level of the RPE in the retinal periphery, which
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Figure 2. Retinal phenotype of patients with LCA5mutations. Right eye shown for each patient. A: Patient #1, age 17 years, with widespread RPE
atrophy, mid-peripheral retinal white dots (white arrow), and peripheral intraretinal pigmentation B: Patient #3, age 5 years, with mid-peripheral
retinal white dots (white arrow) and macular atrophy. C: Patient #4, age 8.5 years, with widespread RPE atrophy and mid-peripheral retinal white
dots (white arrow). D: Patient #14, age 19 years, with retinal white dots (white arrow), peripheral intraretinal pigmentation, and optic disk drusen.
E: Patient #16, age 55 years, with widespread RPE atrophy, foveal preservation, and peripheral intraretinal pigmentation. F: Patient #17, age
18.5 years, with marked macular atrophy and hypopigmented but relatively normal peripheral retina. Intraretinal pigment was seen in the oldest
patients (panels A, D, and E).
were seen in 10 of 14 patients (71%) in whom funduscopic data
were available (Fig. 2). Figure 2B and C shows the white dots clearly,
and document the round, evenly spaced, similar-sized lesions. In-
traretinal pigment migration, when present, was minimal, situated
in the far retinal periphery, and seen in the oldest patients, patients
#1, #6, #7, #14, and #16 (Fig. 2A, D, and E). Macular atrophy was
noted in only three patients, #3, #16, and #17 (Fig. 2B, E, and F);
the macula was otherwise normal on funduscopy in the remaining
patients. In one patient, the macular lesion was particularly severe,
with features of a “macular coloboma” (Fig. 2F). Optic discs were
normal in appearance (pinkdisc color) in all but onepatient (patient
#14), who had optic disc drusen (Fig. 2D). In one family with arRP
(patient #7), we identified a pumpkin-colored maculopathy and
intraretinal pigmentation in the periphery with faintly preserved
islands of RPE (Fig. 3).
OCT data, available for patients #1, #11, and #16, showed preser-
vation of the central foveal inner segment/outer segment (IS/OS)
junctions and of the outer segments in the two younger patients
(#1 and #11) (Fig. 4A and B). In the older patient (#16), OCT
imaging demonstrated macular atrophy, disruption of retinal lami-
nation, and the presence of a hyporeflective well-circumscribed area
in the outer nuclear layer, with a hyperreflective border. This may
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Figure 3. Retinal phenotypeof arRPpatient #7, right eye, age 21 years.
There is widespread RPE atrophy, peripheral preserved islands of RPE
(white arrow), peripheral intraretinal pigmentation, and a “pumpkin”-
colored macula.
represent an area of outer retinal tubulation (also known as rosettes)
(Fig. 4C). OCT image acquisition was otherwise not possible due
to nystagmus. Fundus autofluorescence (FAF) imaging data were
available in two patients (Fig. 5). FAF in patient #1 revealed an over-
all hypofluorescence in the macula, with a central hyperfluorescent
signal in the fovea (Fig. 5A). FAF images of patient #16 showed
severe hypofluorescence in the macula corresponding to significant
RPE atrophy (Fig. 5B). Goldmann perimetry in patient #16 revealed
a small central island, with a relatively large preserved nasal field and
a small temporal field.
Discussion
LCA5 mutations are a rare cause of LCA. Previously, only 12
different mutations had been identified and published in 16 fam-
ilies with LCA. In the current study, which is the largest study to
date, we have screened the coding region of LCA5 in 1,008 patients,
797 with LCA and EORD, and 211 with arRP, ascertained from
eight different countries. We identified mutations in 18 new LCA
families. We discovered 19 different LCA5 mutations, 17 of which
are novel. Mutations in LCA5 thus account for ∼2% of patients
with LCA, EORD, and arRP in our cohort. All 29 different LCA5
variants have now been included in the new Leiden Open Varia-
tionDatabase (LOVD; http://www.LOVD.nl/LCA5). In two patients
(#14 and#15),we identifiedheterozygous variants. The second allele
may have been missed because the variant may be located outside
the protein-coding exons, or because these variants are causative in
a more complex inheritance model (such as digenic), or that these
are coincidental findings of heterozygous variants that play no role
in the LCA phenotype.
The majority of LCA5mutations found both in this study and in
those published previously are likely null mutations due to prema-
ture termination of the protein. Only one missense mutation in this
gene (p.Ser202Pro) has been previously reported in LCA, but with-
out accompanying clinical information [Vallespin et al., 2010b]. We
also identified a missense variant, p.Met1Ile (the start codon), in
patient #4, who carried a diagnosis of LCA, in combination with the
most common LCA5 stop mutation p.Gln279∗. If the next methio-
nine in the open reading frame were to be used instead (at position
336), as the alternative start codon, then two coiled–coiled domains
in the lebercilin protein would be lacking, very likely rendering the
truncated lebercilin inactive. Therefore, thismissensemutationmay
also be a null allele. We also identified another missense mutation,
p.His164Arg. This mutation was found in combination with a novel
nonsense mutation, p.Tyr23∗, in LCA patient #16, but segregation
data are lacking. Thus, we cannot exclude that these variants are in
cis configuration and that they are not causative for the phenotype
in patient #16.
Previously, and in the majority of patients in this study, the phe-
notype reported in association with LCA5 mutations is consistent
with LCA with severely reduced vision at, or near birth, nystagmus,
and a nondetectable (<10μV)ERG [Ahmad et al., 2011; denHollan-
der et al., 2007; Dharmaraj et al., 2000; Gerber et al., 2007; Jacobson
et al., 2009; Mohamed et al., 2003; Ramprasad et al., 2008]. High
hypermetropia is common.The visual acuity is reported to range be-
tween 0.20 to light perception and there is extensive peripheral field
loss. In our study, the majority of patients had a clinical diagnosis of
LCA, with fundus examination revealing widespread atrophy of the
retina and RPE but with little intraretinal pigment migration. On
the clinical examination, we commonly identified scattered white
dots at the level of the RPE (Fig. 2A–D—white arrows). White dots
can be found in other genetic types of LCA, such as RPE65, LRAT,
and CEP290. In RPE65-type LCA, Weleber et al. (2011) suggested
that the white dots might represent accumulations of trans-retinyl
esters. The biochemical make-up of the white dots associated with
LCA5 mutations is as yet unknown. Our LCA5-associated retinal
phenotypes are consistent with the retinal changes observed in other
patients with LCA5 mutations (Figs. 2 and 3) [Ahmad et al., 2011;
Dharmaraj et al., 2000; Gerber et al., 2007; Mohamed et al., 2003;
Ramprasad et al., 2008].
However, in this study, for the first time, we identified an
Iraqi family with two affected sibs who carried a diagnosis of
EORD, because they maintained some useful vision until the age of
10 years. In addition, these siblings had preservation of the periph-
eral islands of RPE (Fig. 3), a phenotype similar to preserved para-
arteriolar retinal pigment epithelium documented by Heckenlively
(1982) and later found to be associated with LCA and arRP patients
with CRB1 mutations [den Hollander et al., 1999; Heckenlively,
1982]. We have thus expanded the phenotypic spectrum associated
with LCA5 mutations, which now includes both EORD and a new
retinal phenotype consisting of preserved islands of peripheral RPE
(Fig. 3).
There is little published data on retinal imaging such as OCT and
FAF imaging inpatientswithLCA5mutations. In this regard,wehere
contribute three new patients with LCA5 mutations and new OCT
and FAF data. However, it is a limitation of the present study that we
were unable to obtain good quality autofluorescence imaging and
OCT on the entire cohort. This was, in part, due to the inherent dif-
ficulties of such imaging in patients with nystagmus, their ages and
their remote living conditions. Jacobson et al. (2009) reported a low
autofluorescent signal corresponding to macular atrophy in two
siblings with a homozygous LCA5 mutation, in whom mutations
in CRB1 had previously been excluded. We demonstrated similar
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Figure 4. Optical coherence tomography imaging of patients with LCA5 variants. A: Patient #1 (age 17 years). B: Patient #11 (age 6 years)—white
arrows demarcate the extent of preservation of the central foveal IS/OS junctions and of the outer segments. C: Patient #16 (age 55 years)
demonstrating macular atrophy, disruption of retinal lamination, and a presumed area of outer retinal tubulation (white arrow).
macular hypoautofluorescence in one subject who in addition had
a small area of hyperautofluorescence at the fovea, suggesting con-
tinued metabolic activity of the foveal cones and RPE. In our study,
OCT imaging was possible in three subjects, and the findings re-
vealed surprising preservation of the central foveal IS/OS junctions
and of the outer segment structures (in the younger patients, of the
age of 17 years and 6 years, respectively). In the older patient, of
the age of 55 years, OCT imaging demonstrated macular atrophy,
loss of the retinal lamination, and probable outer retinal tubulation
(also known as rosettes), a late-stage process in the degeneration
Figure 5. Fundus autofluorescence imaging of patients with LCA5 variants. A: Patient #1 (age 17 years), demonstrating overall macular
hypofluorescence, with a hyperfluorescent foveal signal, suggesting metabolic activity of the foveal cones and RPE complex. B: Patient #16 (age
55 years), showing a large area of macular hypofluorescence corresponding to RPE atrophy.
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of photoreceptors that has been described recently in a number
of retinal conditions (Fig. 4C) [Sergouniotis et al., 2012; Zweifel
et al., 2009]. Previously published OCT findings have demonstrated
loss of the photoreceptor and outer nuclear layers, and abnormal
retinal lamination eccentric to the fovea, but with evidence of a
retained photoreceptor layer at the fovea [Jacobson et al., 2009].
This suggests that in the early stages of the disease, there may be
viable photoreceptors (cones) in the foveal region, which may be
amenable to therapeutic intervention. It is of interest that patient
#14 at the of age of 19, with an advanced stage of disease, still had
a detectable 30 Hz cone ERG in each eye (Table 2) with narrow
band-passed filtering and computer averaging. In future clinical tri-
als, this technique of ERG recording, which is not performed in the
present ISCEV protocol, could be considered as a method of objec-
tively monitoring efficacy or lack of efficacy as undoubtedly most
patients with remaining vision will have a detectable cone ERGwith
this technique.
Lebercilin is expressed in a number of tissues; however, there
have been no reports of extraocular abnormalities in LCA5 mu-
tations. One patient with LCA5 retinopathy died from asphyxia
and the authors propose a possible link between the cause of death
and the presence of lebercilin in the bronchial ciliated epithelial cells
[Ramprasad et al., 2008]. In the present study, one patient had global
developmental delay, whereas another experienced behavioral prob-
lems. Whether this is related to abnormal extraocular expression of
lebercilin remains to be determined.
LCA5-associated LCA is a rare form of severe childhood onset
retinal dystrophy. Most LCA5mutations are null and are associated
with a severe phenotype. Missense mutations are rare and may be
associated with a milder EORD, suggesting that such mutations
may result in some residual protein function. LCA5-type LCA may
be amenable to treatment, but this is more likely to be successful in
young patients.
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